Airsculpt Technologies, Inc. (AIRS) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0094961002

Price
1.67 USD
Market cap
120.40 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Airsculpt Technologies, Inc. financials

Fiscal year2025
Revenue151.82 m USD
Gross profit90.13 m USD
Operating income-11.56 m USD
EBIT-11.56 m USD
Net income-11.67 m USD
Diluted EPS – continuing operations-0.19 USD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Airsculpt Technologies, Inc.

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Tampa, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.